Ovid Therapeutics to Present at Upcoming August Investor Conferences
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving...
Day: July 30, 2024
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74...
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life...
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies...
LifeMD to Report Second Quarter 2024 Financial Results on August 7
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia, including improvement in pain and...
Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes...
aTyr Pharma Announces Research Study with Stanford Medicine
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain...
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of...
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of...
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024...
VitalHub Corp. to Acquire MedCurrent Corporation
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to...
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six...
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools...
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung...
Cytokinetics Announces Call for Proposals for Corporate Giving Program
Program Augments Existing Patient Advocacy and Professional Society Donationsto Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September...
Repligen Reports Second Quarter 2024 Financial Results
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half...
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential...